That’s Natural! is excited about the discoveries being made about cannabidiol (CBD) and the inherent endocannabinoid system that exists in each of our bodies. We hope you will do research for yourself, below are some links to places to start, and here is a helpful info-graphic. You can search the National Institutes of Health or Google Scholar to find research for cannabinoids like CBD!
1- The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system
2- The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors
3- Plant-based medicines for anxiety disorders, part 2: A review of clinical studies with supporting preclinical evidence
4- Effects of cannabidiol (CBD) on regional cerebral blood flow
5- Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation
6- Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients
7- Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder
8- Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug
9- Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa
10- Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors
11- Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
Alzheimer’s & Dementia
1- Endocannabinoid signalling in Alzheimer’s disease
2- A molecular link between the active component of marijuana and Alzheimer’s disease pathology
3- Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells
4- The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer’s Disease
5- Cannabinoids for the treatment of dementia
6- Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression
7- Cannabidiol: A promising drug for neurodegenerative disorders?
8- Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer’s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition
9- The role of the endocannabinoid system in Alzheimer’s disease: facts and hypotheses
10- The role of phytochemicals in the treatment and prevention of dementia
11- Cannabinoids for the treatment of dementia
12- Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement
13- Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
14- In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s Disease
Arthritis & Anti-Inflammatory
1- The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis
2- Involvement of the endocannabinoid system in osteoarthritis
3- The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55
4- Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees
5- Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis
6- Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
7- Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes.
8- Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model.
9- HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.
10- HU-446 and HU-465, Derivatives of the Non-psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells.
11- Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells
1- Mutations found in individuals with autism interfere with endocannabinoid signaling in the brain
2- Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders
3- A novel approach to the symptomatic treatment of autism
4- Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders
5- Targeting the endocannabinoid system in the treatment of fragile X syndrome
Cancer & Tumors
1- Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpes virus-infected endothelium
2- Cannabidiol as potential anticancer drug
3- Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1
4- Cannabidiol inhibits angiogenesis by multiple mechanisms
5- The inhibitory effects of cannabidiol on systemic malignant tumors
6- HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor.
7- Cannabidiol as potential anticancer drug.
1- TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer
1- Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines
2- Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival
3- Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas
4- Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism
5- Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target
6- Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme
7- Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect
8- Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents
1- Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells
2- Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis
3- Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma
4- Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy
5- Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration
1- A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells
2- Endocannabinoids in endocrine and related tumours
1- Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression
1- Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1
2- COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells
3- Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells
Prostate & Colon Cancer
1- Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer
2- Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent
3- In Vitro Anticancer Activity of Plant-Derived Cannabidiol on Prostate Cancer Cell Lines
4- Towards the use of non-psychoactive cannabinoids for prostate cancer
5- Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol
1- Anticancer activity of anandamide in human cutaneous melanoma cells
2- Cannabinoids as therapeutic agents in cancer: current status and future implications
3- Structure-dependent inhibitory effects of synthetic cannabinoids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and skin tumour promotion in mice
4- Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.
5- Cannabinoid receptors as novel targets for the treatment of melanoma.
1- Cannabidiol in inflammatory bowel diseases: a brief overview
2- Cannabis finds its way into treatment of Crohn’s disease
3- Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis
4- Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis
5- The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis
6- Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice
7- Hergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis
8- Endocannabinoids and the gastrointestinal tract
9- Cannabinoids and the gut: New developments and emerging concepts
10- Cannabinoids and gastrointestinal motility: Animal and human studies
1- Altered Expression of Type-1 and Type-2 Cannabinoid Receptors in Celiac Disease
1- Cannabidiol arrests onset of autoimmune diabetes in NOD mice –
2- Cannabidiol Attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic Cardiomyopathy
3- Cannabidiol lowers incidence of diabetes in non-obese diabetic mice
4- Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption
5- Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes
1- Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects
2- Cannabidiol–recent advances.
3- Known Pharmacological Actions of Nine Nonpsychotropic Phytocannabinoids.
4- Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.
5- Molecular Targets of Cannabidiol in Neurological Disorders.
1- Update: Clinical Challenges in the Diagnosis And Management of Fibromyalgia
2- Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
3- Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life.
Heart & Circulatory Health – Atherosclerosis
1- The role of the endocannabinoid system in atherosclerosis
2- Cannabinoid receptors in atherosclerosis
3- The potential use of cannabidiol in the therapy of metabolic syndrome
1- Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpes virus-infected endothelium
1- Antibacterial cannabinoids from Cannabis sativa: A structure-activity study
2- Antibacterial activity of delta9-tetrahydrocannabinol and cannabidiol
MRSA (Methicillin-resistant Staphylococcus aureus)
Antimicrobial and Antiparasitic (+)-trans-Hexahydrodibenzopyrans and Analogues from Machaerium multiflorum
Antibacterial Cannabinoids from Cannabis sativa: A Structure−Activity Study
1- Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
2- Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.
3- Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw
4- Cannabidiol—transdermal delivery and anti-inflammatory effect in a murine model
5- Mediation of Cannabidiol Anti-inflammation in the Retina by Equilibrative Nucleoside Transporter and A2A Adenosine Receptor
6- The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain
7- Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats
ADD & ADHD
1- Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats
2- Subtypes of Attention Deficit — Hyperactivity Disorder (ADHD) and cannabis use
1- Cannabidiol for the treatment of cannabis withdrawal syndrome
2- Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder
3- Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity
4- Dysregulation of cannabinoid CB1 receptor and associated signaling networks in brains of cocaine addicts and cocaine-treated rodents
5- Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010
6- Impact of Cannabis Use during Stabilization on Methadone Maintenance Treatment
7- Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats
8- Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances
9- Cannabidiol inhibits the reward-facilitating effect of morphine
10- Inhibition of monoacylglycerol lipase enzyme reduces nicotine withdrawal
11- Cannabidiol reduces cigarette consumption in tobacco smokers
12 – Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage.
13 – Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence.
14 – Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances.
1- The role of the endocannabinoid system in eating disorders: Neurochemical and behavioral preclinical evidence
2- Cancer cachexia and cannabinoids
3- Leptin, ghrelin, and endocannabinoids: Potential therapeutic targets in anorexia nervosa
1- Cannabinoids in bipolar affective disorder: A review and discussion of their therapeutic potential
2- Cannabidiol was ineffective for manic episode of bipolar affective disorder
1. The endocannabinoid system and migraine.
2. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
ALS (Lou Gehrig’s Disease)
1- Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials
1- Cannabidiol for the treatment of psychosis in Parkinson’s disease
2- Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: Importance of antioxidant and cannabinoid receptor-independent properties
3- Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson’s disease
4- Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial
1- Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors
2- Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow
3- The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD)
4- Cannabidiol as a Potential Treatment for Anxiety Disorders
5- Cannabinoids as therapeutic for PTSD
1- Cannabidiol as a Treatment for Acne?
2- Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes
3- The endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities
4- Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling
5- Endocannabinoid signaling and epidermal differentiation
1- Use of cannabidiol prodrugs in topical and transdermal administration with microneedles
2- Anti-microbial composition comprising cannabinoids
3- The Endocannabinoid System and Its Role in Eczematous Dermatoses
1- Pharmacological treatment of psoriasis
2- Cannabis for Refractory Psoriasis—High Hopes for a Novel Treatment and a Literature Review
3- Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis
4- Epigenetic control of skin differentiation genes by phytocannabinoids
5- Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression
6- The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities
1- Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats
2- Hypnoticlike effects of cannabidiol in the rat
3- Effect of cannabidiol on cytochrome P-450 and hexobarbital sleep time
4- Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats
5- Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats
1- Intraocular pressure following systemic administration of cannabinoids.
2- Cannabinoids in glaucoma II: the effect of different cannabinoids on intraocular pressure of the rabbit.
3- Cannabidiol protects retinal neurons by preserving glutamine synthetase activity in diabetes
4- Neuroprotective Effect of Cannabidiol in Endotoxin-Induced Retinal Inflammation
5- Cannabidiol Dampens Streptozotocin-Induced Retinal Inflammation by Targeting of Microglial Activation
6- Endocannabinoid signaling enhances visual responses through modulation of intracellular chloride levels in retinal ganglion cells
7- Cannabinoids and glaucoma
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.